Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Talarico, Giovanna ^a   Orecchioni, Stefania ^a   Dallaglio, Katiuscia ^b   Reggiani, Francesca ^a   Mancuso, Patrizia ^a   Calleri, Angelica ^a   Gregato, Giuliana ^a   Labanca, Valentina ^a   Rossi, Teresa ^b   Noonan, Douglas M ^c,d   Albini, Adriana ^c   Bertolini, Francesco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b IRCCS   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ATENOLOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TUMOR MARKER;

ANIMAL; APOPTOSIS; BREAST NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; FEMALE; HUMAN; METABOLISM; METASTASIS; PATHOLOGY; STEM CELL; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE, WHITE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPIRIN; ATENOLOL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ELECTRON TRANSPORT COMPLEX I; FEMALE; HUMANS; METFORMIN; NAD; NEOPLASM METASTASIS; STEM CELLS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84953205676     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18673     Document Type: Article

References (38)

1. Yin, M., Zhou, J., Gorak, E. J. & Quddus, F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes. A systematic review and meta-analysis. The Oncologist. 18, 1248-55 (2013).
2. Goodwin, P. J., Thompson, A. M. & Stambolic, V. Diabetes, metformin, and breast cancer: lilac time? J Clin Oncol. 30, 2812-4 (2012).
3. Decensi, A. et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 3, 1451-61 (2010).
4. Cazzaniga, M. et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer. 109, 2792-7 (2013).
5. Niraula, S. et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat. 135, 821-30 (2012).
6. Zannella, V. E. et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res. 19, 6741-50 (2013).
7. Checkley, L. A. et al. Metformin inhibits skin tumor promotion in overweight and obese mice. Cancer Prev Res (Phila). 7, 54-64 (2014).
8. Blandino, G. et al. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun. 3, 865 (2012).
9. Zhu, P. et al. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila). 7, 199-210 (2014).
10. Oliveras-Ferraros, C. et al. Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. Cell Cycle. 13, 1132-44 (2014).
11. Morgillo, F. et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res. 19, 3508-19 (2013).
12. Menendez, J. A. et al. Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle. 11, 2782-92 (2012).
13. Berstein, L. M. Metformin in obesity, cancer and aging: addressing controversies. Aging (Albany NY). 4, 320-9 (2012).
14. Li, L. et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res. 20, 2714-26 (2014).
15. Ma, J. et al. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC Cancer. 14, 172 (2014).
16. Pernicova, I. & Korbonits, M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 10, 143-56 (2014).
17. Orecchioni, S. et al. The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. Int J Cancer. 136, E534-44 (2015).
18. Birsoy, K. et al. Metabolic determinants of cancer cell sensitivity to glucose limitations and biguanides. Nature. 508, 108-12 (2014).
19. Foretz, M., Guigas, B., Bertrand, L., Pollak, M. & Viollet, B. Metformin: from mechanisms of action to therapy. Cell Metab. 20, 953-66 (2014).
20. Marzbani, E., Inatsuka, C., Lu, H. & Disis, M. L. The invisible arm of immunity in common cancer chemoprevention agents. Cancer Prev Res (Phila). 6, 764-73 (2013).
21. Eikawa, S. et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA 112, 1809-14 (2015).
22. Dallaglio, K. et al. Paradoxic effects of Metformin on endothelial cells and angiogenesis. Carcinogenesis. 35, 1055-66 (2014).
23. Owen, M. R., Doran, E. & Halestrap, A. P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrialrespiratory chain. Biochem J. 348, Pt 3, 607-14 (2000).
24. Martin-Montalvo, A. et al. Metformin improves healthspan and lifespan in mice. Nat Communications. 4, 2192e (2013).
25. Din Kwan, M. L., Habel, L. A., Slattery, M. L. & Caan, B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control. 18, 613-20 (2007).
26. Blair, C. K., Sweeney, C., Anderson, K. E. & Folsom, A. R. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat. 101, 191-197 (2007).
27. Holmes, M. D. et al. Aspirin intake and survival after breast cancer. J Clin Oncol 28, 1467-1472 (2010).
28. Botteri, E. et al. Therapeutic effect of beta-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat. 140, 567-75 (2013).
29. Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K. & Visvanathan, K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 29, 2635-44 (2011).
30. Pasquier, E. et al. β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer. 108, 2485-94 (2013).
31. Monami, M. et al. Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials. Curr Med Res Opin. 29, 369-78 (2013).
32. Yue, W., Yang, C. S., DiPaola, R. S. & Tan, X. L. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res (Phila). 7, 388-97 (2014).
33. Din, F. V. et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 142, 1504-15.e3 (2012).
34. Queiroz, E. A. et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One 9, e98207 (2014).
35. Hawley, S. A. et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 336, 918-22 (2012).
36. Martin-Padura, I. et al. The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression. Cancer Res. 72, 325-34 (2012).
37. Orecchioni, S. et al. Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis and metastasis of breast cancer. Cancer Res. 73, 5880-91 (2013).
38. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R. & Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 54, 105-15 (1988).